Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer's disease

Evlice A. T., Ulusu N. N.

ACTA NEUROLOGICA BELGICA, vol.117, no.1, pp.229-234, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 117 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1007/s13760-016-0666-6
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.229-234
  • Çukurova University Affiliated: Yes


Alzheimer's disease (AD) is a multi-factorial neurodegenerative disorder that numerous factors have key properties in the development of this proteopathy. Glucose-6-phosphate dehydrogenase (G6PD) is the most common form of enzymopathy. We have examined G6PD enzyme activity levels in the serum of newly diagnosed AD patients compared with control subjects without dementia from the both sexes. Serum G6PD levels were found to be significantly higher (approximately two times) in AD patients compared to control geriatric subjects in both sexes. We have concluded that G6PD seems to play an integral role in the progress and/or prevention of AD.